Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04025216 2024-01-24

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Phase 1 Terminated

16 enrolled

BreastGynecologicPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02096614 2021-06-18

Investigator Initiated Phase 1 Study of TBI-1201

Phase 1 Completed

18 enrolled

DermatologicGastrointestinalGynecologicHead & Neck

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms

NCT01312376 2020-04-24

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Phase 1 Terminated

18 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02366546 2018-10-24

Investigator Initiated Phase 1 Study of TBI-1301

Phase 1 Unknown

9 enrolled

DermatologicGastrointestinalGynecologicHead & NeckSarcoma

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT02118285 2017-12-05

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1 Completed

2 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02482090 2017-08-16

TIL Therapy for Metastatic Ovarian Cancer

Phase 1 Completed

6 enrolled

Gynecologic

Ovarian Neoplasms

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Phase 1 Unknown

36 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

Clinical Trials

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

ACTolog

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Investigator Initiated Phase 1 Study of TBI-1201

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Investigator Initiated Phase 1 Study of TBI-1301

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

TIL Therapy for Metastatic Ovarian Cancer

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies